The Immune Analysis Facility (IAF), part of the Center for Immunotherapy at Roswell Park Cancer Institute, is a shared resource responsible for serial monitoring of immunologic functions in patients with cancer, those who are treated with biologic therapies, and those who participate in clinical trials or research protocols at the RPCI. The development of immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The IAF makes available to its users a broad range of state-of-the-art immunologic assays, performed under a rigorous quality control program. In addition, as advances in immunobiology occur and new assays are requested by the users, the IAF performs pre-clinical evaluations of the assays and, when they become reliable and standardized, adds them to the available assay list. The ultimate goal of the facility is to continuously develop cutting-edge immune monitoring technology.
The IAF offers consultation regarding optimal immunologic assessment and assay development for innovative approaches to evaluate immune responses. We provide expert advice regarding the types of assays for immune monitoring and data interpretation tailored to fit the endpoints of each specific clinical trial.
The IAF maintains extensive quality control (QC) and quality assurance (QA) programs to ensure the validity of test results. We are currently participating in a worldwide immune monitoring consortium to standardize and validate immune assays and establish rigorous quality control standards. The IAF has established a fee-for-service schedule which gives priority to RPCI members. Interested investigators will be asked to provide a summary of their clinical trial design, which will be reviewed by the facility in order to design the appropriate methodology to successfully measure the endpoints of the study.
This assay is used to detect and quantify the number of T cells that secrete a particular cytokine (e.g. Interferon-γ) upon recognition of a specific antigen. T cells are cultured with antigen-presenting cells in wells coated with an antibody recognizing a particular cytokine. The coating antibody captures the secreted cytokine and a second cytokine-specific antibody is coupled to a chromogenic substrate and used for detection. Results appear as spots, with each spot corresponding to one cytokine-secreting cell. The number of spots equals the number of cytokine-secreting cells for a specific antigen. However this assay does not determine the amount of cytokine secreted. This assay is highly sensitive (1 cell in 100,000) and can be performed directly ex-vivo using relatively few T cells.
Immune Analysis Shared Resource has not received any reviews.
Immune Analysis Shared Resource has not received any endorsements.